Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Investigation of photopheresis as new therapy regimen in patients with bronchiolitis obliterans syndrome after lung transplantation in a controlled, randomized study
| Condition | Intervention |
|---|---|
|
Bronchiolitis Obliterans |
Procedure: photopheresis |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation |
- FEV1 stabilisation [ Time Frame: 6 month ] [ Designated as safety issue: Yes ]
| Enrollment: | 12 |
| Study Start Date: | August 2007 |
| Study Completion Date: | March 2010 |
| Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: 1
Observation with standard care (macrolides, exercise, oxygen therapy etc.) alone.
|
Procedure: photopheresis
2-day cycles of photopheresis every 3 weeks for 3 months
Other Name: photopheresis by Therakos
|
|
Active Comparator: 2
2-day cycles of photopheresis every 3 weeks for 3 months
|
Procedure: photopheresis
2-day cycles of photopheresis every 3 weeks for 3 months
Other Name: photopheresis by Therakos
|
Detailed Description:
Bronchiolitis obliterans syndrome is the major cause of mortality after lung transplantation. 5 years after lung transplantation about 50% of all patients have this syndrome. There are nearly none therapy options. Besides effective therapy of any gastrooesophageal reflux and an oral medication with azithromycin none further regimens are known. Photopheresis could show in several studies a benefit for patients with gvhd after bone marrow transplantation or for chronic rejection after any other solid organ transplantation. Just little case reports could show beneficial effect in patients with bos after lung transplantation.
This is the first controlled, randomized study with patients with bos after lung transplantation to investigate the effectiveness of this therapy in that patients.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Single/Double lung transplantation
- at least 6 months after lung transplantation
- bronchiolitis obliterans syndrome, Stadium > 1 (nach ISHLT 2001, FEV1 <80% Best), none other reason for worsening lung function (eg acute rejection, infection, extrapulmonary reasons, airway obstruction)
- none gastroesophageal reflux
- medication for > 3 months with Azithromycin with further decrease of FEV1, MEF 25-75
- bioptic prove that there is no acute rejection
- no improvement under steroid pulse therapy
Exclusion Criteria:
- tumor or hematologic disease
- acute rejection
- respiratory insufficiency (O2>2l/min, pCO2 >50 mm Hg)
- weight < 40 kg
- acute infection
- colonization with multiresistant pathogens
Contacts and Locations| Germany | |
| Medizinische Hochschule Hannover, Dep. Pneumology | |
| Hannover, Niedersachsen, Germany, 30625 | |
| Department Pneumology, Medizinische Hochschule Hannover | |
| Hannover, Niedersachsen, Germany, 30625 | |
| Principal Investigator: | Fuehner Thomas, Doctor | Department Pneumology |
More Information
No publications provided
| Responsible Party: | Department for Respiratory Medicine, Hannover Medical School |
| ClinicalTrials.gov Identifier: | NCT00502554 History of Changes |
| Other Study ID Numbers: | 4584 |
| Study First Received: | July 16, 2007 |
| Last Updated: | July 25, 2011 |
| Health Authority: | Germany: Ethics Commission |
Keywords provided by Hannover Medical School:
|
lung function FEV1 |
Additional relevant MeSH terms:
|
Bronchiolitis Bronchiolitis Obliterans Bronchitis Bronchial Diseases |
Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Tract Infections |
ClinicalTrials.gov processed this record on June 18, 2013